Literature DB >> 21335559

A peptide found by phage display discriminates a specific structure of a trisaccharide in heparin.

Tomio Yabe1, Ritsuko Hosoda-Yabe, Yoshihiro Kanamaru, Makoto Kiso.   

Abstract

A number of recent studies have shown that heparan sulfate can control several important biological events on the cell surface through changes in sulfation pattern. The in vivo modification of sugar chains with sulfates, however, is complicated, and the discrimination of different sulfation patterns is difficult. Heparin, which is primarily produced by mast cells, is closely approximated by the structural analog heparan sulfate. Screening of heparin-associating peptides using phage display and antithrombin-bound affinity chromatography identified a peptide, heparin-associating peptide Y (HappY), that acts as a target of immobilized heparin. The peptide consists of 12 amino acid residues with characteristic three arginines and exclusively binds to heparin and heparan sulfate but does not associate with other glycosaminoglycans. HappY recognizes three consecutive monosaccharide residues in heparin through its three arginine residues. HappY should be a useful probe to detect heparin and heparan sulfate in studies of glycobiology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21335559      PMCID: PMC3069443          DOI: 10.1074/jbc.M110.172155

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  54 in total

1.  An IKLLI-containing peptide derived from the laminin alpha1 chain mediating heparin-binding, cell adhesion, neurite outgrowth and proliferation, represents a binding site for integrin alpha3beta1 and heparan sulphate proteoglycan.

Authors:  K Tashiro; A Monji; I Yoshida; Y Hayashi; K Matsuda; N Tashiro; Y Mitsuyama
Journal:  Biochem J       Date:  1999-05-15       Impact factor: 3.857

2.  A color reaction of pentose phosphate esters substituted in position 5.

Authors:  Z DISCHE; E LANDSBERG
Journal:  Biochim Biophys Acta       Date:  1957-04

3.  P-Selectin-mediated acute inflammation can be blocked by chemically modified heparin, RO-heparin.

Authors:  Yanguang Gao; Na Li; Rui Fei; Zhihong Chen; Sheng Zheng; Xianlu Zeng
Journal:  Mol Cells       Date:  2005-06-30       Impact factor: 5.034

4.  The role of Arg46 and Arg47 of antithrombin in heparin binding.

Authors:  V Arocas; S C Bock; S T Olson; I Björk
Journal:  Biochemistry       Date:  1999-08-03       Impact factor: 3.162

5.  A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry.

Authors:  D Shukla; J Liu; P Blaiklock; N W Shworak; X Bai; J D Esko; G H Cohen; R J Eisenberg; R D Rosenberg; P G Spear
Journal:  Cell       Date:  1999-10-01       Impact factor: 41.582

6.  Requirement for anticoagulant heparan sulfate in the fibroblast growth factor receptor complex.

Authors:  W L McKeehan; X Wu; M Kan
Journal:  J Biol Chem       Date:  1999-07-30       Impact factor: 5.157

7.  Enzymatic synthesis of heparin related polysaccharides on sensor chips: rapid screening of heparin-protein interactions.

Authors:  Eva Muñoz; Ding Xu; Fikri Avci; Melissa Kemp; Jian Liu; Robert J Linhardt
Journal:  Biochem Biophys Res Commun       Date:  2005-11-17       Impact factor: 3.575

8.  Developmental and regional expression of heparan sulfate sulfotransferase genes in the mouse brain.

Authors:  Tomio Yabe; Toshihiro Hata; Jue He; Nobuaki Maeda
Journal:  Glycobiology       Date:  2005-06-08       Impact factor: 4.313

9.  Antithrombin-S195A factor Xa-heparin structure reveals the allosteric mechanism of antithrombin activation.

Authors:  Daniel J D Johnson; Wei Li; Ty E Adams; James A Huntington
Journal:  EMBO J       Date:  2006-04-13       Impact factor: 11.598

Review 10.  Interactions between heparan sulfate and proteins: the concept of specificity.

Authors:  Johan Kreuger; Dorothe Spillmann; Jin-ping Li; Ulf Lindahl
Journal:  J Cell Biol       Date:  2006-07-31       Impact factor: 10.539

View more
  1 in total

1.  Sialic acid deposition impairs the utility of AAV9, but not peptide-modified AAVs for brain gene therapy in a mouse model of lysosomal storage disease.

Authors:  Yong Hong Chen; Kristin Claflin; James C Geoghegan; Beverly L Davidson
Journal:  Mol Ther       Date:  2012-05-15       Impact factor: 11.454

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.